SHUTTLE PHARMACEUTICALS, INC.
1 RESEARCH COURT, SUITE 450
ROCKVILLE, MD 20850
May 8, 2017
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Mail Stop 4546
100 “F” Street, N.E.
Washington, D.C. 20549-3629
Attention: | Ms. Mary Beth Breslin |
Mr. Jeffrey Gabor | |
Ms. Keira Nakada | |
Ms. Mary Mast |
Re: | Shuttle Pharmaceuticals, Inc. (the “Company”) | |
Registration Statement on Form S-1, as amended, | ||
File No. 333-215027 |
Ladies and Gentleman:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, the Company respectfully requests that the effective date of the Registration Statement is accelerated so that it will become effective at 4:00 p.m. Eastern Time on Wednesday, May 10, 2017, or as soon thereafter as practicable.
If you have any further questions or comments, kindly contact the undersigned at (240) 403-4212 or our counsel, Dale S. Bergman, Esq. of Gutiérrez Bergman Boulris, PLLC at (786) 888-1744.
Very truly yours,
SHUTTLE PHARMACEUTICALS, INC.
By: | /s/ Anatoly Dritschilo | |
Anatoly Dritschilo, M. D. | ||
Chief Executive Officer |